FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Peptide Library

Sermorelin

Geref / GHRH 1-29 / GRF 1-29

Growth Hormone Secretagogues

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid native GHRH sequence. Originally FDA-approved as Geref for pediatric growth hormone deficiency diagnostics and treatment, it remains one of the most widely compounded peptides for age-related GH decline. Its mechanism preserves natural pulsatile GH release patterns and hypothalamic-pituitary feedback loops, distinguishing it from exogenous growth hormone administration.

Mechanism of Action

Synthetic analog of the first 29 amino acids of endogenous GHRH. Stimulates pituitary somatotrophs to release GH in a physiologic, pulsatile pattern. Preserves negative feedback through somatostatin, preventing supraphysiologic GH levels.

Research Protocols

For research purposes only. Not medical advice.

Research protocols use 200-500mcg daily via subcutaneous injection at bedtime to coincide with natural nocturnal GH surge. Continuous use for 3-6 months. Often combined with a GHRP.

Research Notes

Clinical Research Status

Sermorelin was FDA-approved in 1997 as Geref Diagnostic (IV) and Geref (subcutaneous) for pediatric GH deficiency but was voluntarily discontinued by EMD Serono in 2008 for commercial reasons, not safety concerns. It remains available through compounding pharmacies under physician supervision and is one of the most prescribed peptides in anti-aging medicine. Phase IV post-marketing data accumulated over a decade of clinical use established a strong safety profile.

Key Published Findings

Clinical trials demonstrated significant increases in IGF-1 levels, lean body mass, and decreased visceral adiposity in GH-deficient patients. A 2012 study in the Journal of Clinical Endocrinology & Metabolism showed improved sleep quality and increased slow-wave sleep duration. Research indicates sermorelin preserves the natural GH pulsatile secretion pattern, unlike exogenous GH which suppresses endogenous production. Long-term studies showed sustained benefits over 6-12 months without tachyphylaxis.

Safety Profile

Sermorelin has one of the most established safety profiles among GH-related peptides due to its decade of FDA-approved clinical use. Common side effects are limited to injection site reactions, facial flushing, and transient headache. Because it works through the hypothalamic-pituitary axis, overdose risk is self-limiting as the body's negative feedback mechanisms remain intact. No significant adverse cardiovascular or oncological signals emerged during post-marketing surveillance.

Drug Interactions & Contraindications

Contraindicated in patients with active malignancy due to theoretical concerns about GH-mediated tumor growth promotion. Glucocorticoids may blunt the GH response to sermorelin, and concurrent use with somatostatin analogs (octreotide) will antagonize its effects. Patients on thyroid hormone replacement should have levels monitored as GH can increase T4 to T3 conversion. Caution advised in patients with obesity as adiposity reduces GH response to GHRH stimulation.

Comparison to Related Compounds

Unlike CJC-1295, sermorelin has a shorter half-life (10-20 minutes) requiring more frequent dosing but producing more physiologic GH pulses. Compared to tesamorelin (the only currently FDA-approved GHRH analog, for HIV lipodystrophy), sermorelin is less potent but more widely accessible through compounding. It is considered gentler than ipamorelin/CJC-1295 combinations and is often recommended as a starting point for GH optimization. Relative to exogenous GH, sermorelin maintains feedback regulation and does not suppress endogenous production.

Community Observations

Users commonly report improved sleep quality within the first 1-2 weeks, with body composition changes becoming apparent at 3-6 months. The peptide is typically dosed at 200-300 mcg subcutaneously before bedtime to synergize with natural nocturnal GH secretion. Some practitioners cycle sermorelin (5 days on, 2 days off) though clinical data supporting cycling protocols is limited. It is frequently combined with ipamorelin (a GHSP) for synergistic GH release through complementary receptor pathways.

Half Life

~10-20 minutes

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 18 months.

Reconstituted

Refrigerate 2-8C. Use within 14 days.

US Legal Status

Research chemical (formerly FDA-approved)

Also Known As

GerefGHRH 1-29GRF 1-29

Frequently Asked Questions

What is Sermorelin?

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid native GHRH sequence. Originally FDA-approved as Geref for pediatric growth hormone deficiency diagnostics and treatment, it remains one of the most widely compounded peptides for age-related GH decline. Its mechanism preserves natural pulsatile GH release patterns and hypothalamic-pituitary feedback loops, distinguishing it from exogenous growth hormone administration.

How does Sermorelin work?

Synthetic analog of the first 29 amino acids of endogenous GHRH. Stimulates pituitary somatotrophs to release GH in a physiologic, pulsatile pattern. Preserves negative feedback through somatostatin, preventing supraphysiologic GH levels.

What is the US regulatory status of Sermorelin?

Research chemical (formerly FDA-approved)

What is the half-life of Sermorelin?

~10-20 minutes

What else is Sermorelin called?

Geref, GHRH 1-29, GRF 1-29

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer